Ana Alcaráz-Sanabria

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer

Ana Alcaráz-Sanabria, Cristina Nieto‐Jiménez, Verónica Corrales‐Sánchez et al. · Molecular Cancer Therapeutics · 2017 · 63 citations · Full text

Medicine, Cell Biology, Oncology +17

Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

Ana Alcaráz-Sanabria, Mariona Baliu‐Piqué, Cristina Sáiz-Ladera et al. · Frontiers in Oncology · 2020 · 61 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

Cristina Nieto‐Jiménez, Ana Alcaráz-Sanabria, Javier Pérez‐Peña et al. · Oncotarget · 2017 · 26 citations · Full text

Medicine, Cancer Biology, Oncology +14

<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases

Alberto Ocaña, Javier Pérez‐Peña, Ana Alcaráz-Sanabria et al. · Oncotarget · 2016 · 23 citations · Full text

Medicine, Bioinformatics, Oncology +17

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors

Javier Pérez‐Peña, Ana Alcaráz-Sanabria, Cristina Nieto‐Jiménez et al. · Oncotarget · 2017 · 23 citations · Full text

Medicine, Genetics, Oncology +11